United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 13

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 13 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderCo-Diagnostics · 48

Strongest available pathenVVeno Medical · -95.9%

Widest latest marginGlucoTrack · 1296.2%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1CODX · Nasdaq

Co-Diagnostics

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2012Salt Lake City, Utah$8.4M market cap

View full Companies Radar profile

48Cautious

Snapshot price$1.21as of page date

Monthly-close return-99.6%five-year window

FY2025 revenue$0.00BCo-Diagnostics, Inc.

Net margin-7533.6%FY2025

P/E snapshot-1.5xone ratio, not a verdict

Prism attention39.4%share across these five

Filing track recordRevenue, USD billions

-99.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -71.8%

52-week position1% through range

$0.94$46.50

News mentions1.1K

Community mentions0partial coverage

U.S.-scope patents2

Prism InsightsWhat sits behind the readiness signal
Observed risk 8/100higher means more observed risk

Earnings signal70/100
Management stability90/100
Market position3/100
Capital-event signal76/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 3 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2PAVM · Nasdaq

PAVmed

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2014New York City, New York$39.3M market cap

View full Companies Radar profile

48Cautious

Snapshot price$4.92as of page date

Monthly-close return-99.8%five-year window

FY2025 revenue$0.00BPAVmed Inc.

Net margin564.8%FY2025

P/E snapshot-2.1xone ratio, not a verdict

Prism attention24.7%share across these five

Filing track recordRevenue, USD billions

-85.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -38.6%

52-week position4% through range

$3.85$28.44

News mentions671

Community mentions0partial coverage

U.S.-scope patents122

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal55/100
Management stability90/100
Market position3/100
Capital-event signal67/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3GCTK · Nasdaq

GlucoTrack

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2001Rutherford, New Jersey$3.4M market cap

View full Companies Radar profile

44Cautious

Snapshot price$4.23as of page date

Monthly-close return-100.0%five-year window

FY2020 revenue$0.00BGlucotrack, Inc.

Net margin1296.2%FY2020

P/E snapshot0.2xone ratio, not a verdict

Prism attention12.1%share across these five

Filing track recordRevenue, USD billions

+378.3%

FY2018–FY2020 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 118.7%

52-week position29% through range

$0.25$14.14

News mentions328

Community mentions0partial coverage

U.S.-scope patents10

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal36/100
Management stability90/100
Market position3/100
Capital-event signal87/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4LYRA · OTC

Lyra Therapeutics

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2005Watertown, Massachusetts$0.4M market cap

View full Companies Radar profile

40Cautious

Snapshot price$0.20as of page date

Monthly-close return-99.9%five-year window

FY2025 revenue$0.00BLyra Therapeutics, Inc.

Net margin-7266.1%FY2025

Prism attention12.5%share across these five

Filing track recordRevenue, USD billions

+39.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 8.7%

52-week position2% through range

$0.00$8.75

News mentions339

Community mentions5partial coverage

U.S.-scope patents72

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal46/100
Management stability90/100
Market position0/100
Capital-event signal46/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5NVNO · Nasdaq

enVVeno Medical

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1999Irvine$7.5M market cap

View full Companies Radar profile

25Avoid

Snapshot price$10.75as of page date

Monthly-close return-95.9%five-year window

FY2020 revenue$0.00BenVVeno Medical Corp

Net margin-29240.1%FY2020

P/E snapshot-1.7xone ratio, not a verdict

Prism attention11.3%share across these five

Filing track recordRevenue, USD billions

-83.3%

FY2018–FY2020 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -59.1%

52-week position8% through range

$8.67$35.70

News mentions306

Community mentions0partial coverage

U.S.-scope patents53

Prism InsightsWhat sits behind the readiness signal
Observed risk 7/100higher means more observed risk

Earnings signal26/100
Management stability90/100
Market position0/100
Capital-event signal15/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 2 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

enVVeno Medical

-95.9%

Co-Diagnostics

-99.6%

PAVmed

-99.8%

Lyra Therapeutics

-99.9%

GlucoTrack

-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Co-Diagnostics

$0.00B

PAVmed

$0.00B

GlucoTrack

$0.00B

Lyra Therapeutics

$0.00B

enVVeno Medical

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

GlucoTrack

1296.2%

PAVmed

564.8%

Lyra Therapeutics

-7266.1%

Co-Diagnostics

-7533.6%

enVVeno Medical

-29240.1%

Prism news attention

Normalized share across these five names; attention is not quality.

Co-Diagnostics

39.4%

PAVmed

24.7%

Lyra Therapeutics

12.5%

GlucoTrack

12.1%

enVVeno Medical

11.3%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Co-Diagnostics leads the conversation

It holds 39.4% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $0.00B.

Price path

enVVeno Medical leads the available price paths

Its monthly-close return is -95.9% for the five-year window. At the other end, GlucoTrack is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

GlucoTrack has the widest latest margin

Its FY2020 net margin is 1296.2%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

PAVmed shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -2.1x while its five-year window price return is -99.8%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · CODX

Co-Diagnostics

1,074available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Legal, arbitration & regulatory

Capital allocation & transactions

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+104.3%190 latest 12m vs 93 prior 12m

Machine-classified coverage tone

83.2% positive+7.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

pcr testing 19molecular diagnostics 19stock price 17stock performance 16earnings report 13share price 13rt-pcr diagnostics 12rapid antigen tests 12

Keyword tag occurrences in available Prism news records.

Coverage: 2011-04-01–2026-06-03 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

CODX

Co-Diagnostics

through 2026-04-02

Earnings releases 18Regulatory 3Listing / IPO 2Leadership changes 1

2026-04-02
Regulatory
The parallel pursuit of commercial expansion in India, South Asia, and Saudi Arabia, alongside ongoing US regulatory review of the Co-Dx PCR platform, represents a geographically ambitious but financially stretched multi-front strategy for a company of this size.
2025-10-28
Listing / IPO
In a separate filing, Co-Diagnostics disclosed an at-the-market equity offering program of up to $10 million through an Equity Distribution Agreement with Maxim Group LLC.
2025-08-15
Earnings releases
Revenue of $0.2 million , which declined from $2.7 million during Q2 2024 primarily due to timing of grant revenue recognition.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PAVM

PAVmed

through 2026-04-02

Earnings releases 15Company announcements 11Leadership changes 2

2026-04-02
Leadership changes
today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's current and future medical device portfolio.
2026-03-30
Earnings releases
GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per common share on a diluted basis.
2026-03-16
Company announcements
PAVmed Inc. (Nasdaq: PAVM) "PAVmed" or the "Company", today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

GCTK

GlucoTrack

through 2026-04-12

Company announcements 4Leadership changes 2Listing / IPO 2Earnings releases 1M&A 1

2026-04-12
Earnings releases
The company reported ($3.98) EPS for the quarter.
2025-11-03
Company announcements
Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it will reconvene a Special Meeting of Shareholders (the “Special Meeting”) on November 7, 2025, at 12 p.m. ET.
2025-09-15
M&A
GlucoTrack shares jumped 117% on Friday after the company entered into a purchase agreement with Sixth Borough Capital.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LYRA

Lyra Therapeutics

through 2025-08-12

Earnings releases 5Company announcements 1

2025-08-12
Earnings releases
Lyra Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2025 and provided a corporate update.
2024-08-15
Company announcements
Lyra Therapeutics pauses development of chronic rhinosinusitis drug: The company now plans to focus on two Phase 3 trials evaluating a different candidate, LYR-210, in chronic rhinosinusitis with and without nasal polyps. It expects to have the first data from the trials by the end of the year and another readout in the first half of 2025. — Katherine Lewin
2025-08-12
Earnings releases
Lyra reported its financial results for the second quarter ended June 30, 2025 and provided a corporate update.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NVNO

enVVeno Medical

through 2026-02-04

Regulatory 7Earnings releases 5Company announcements 1Leadership changes 1Listing / IPO 1

2026-02-04
Company announcements
The Company has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
2025-10-31
Earnings releases
"The Company reported net losses of $4.5 million and $5.6 million for the three months ended September 30, 2025 and 2024, respectively, representing a decrease in net loss of $1.1 million, or 20%, due to a decrease in operating expenses of $1.3 million, partially offset by a decrease in other income of $0.2 million."
2025-09-26
Regulatory
The FDA Medical Devices and Radiological Health Centre had previously issued a letter of refusal of approval in response to the pre-market authorization application for enVVeno for this surgical venous valve.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records

Latest 12m volume+8.7%36648 vs 33721 records

Positive classified tone66.7%+5.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,802

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,579

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 61–65. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Co-Diagnostics leads the readiness ranking

Its Prism readiness score is 48/100, the highest in this five-company comparison.

Open Co-Diagnostics in Companies Radar

Scale and margin leadership sit with Co-Diagnostics and GlucoTrack

Co-Diagnostics has the largest displayed latest revenue at $0.00B; GlucoTrack has the widest displayed latest margin at 1296.2%.

Open Co-Diagnostics in Companies Radar Open GlucoTrack in Companies Radar

Comparisons

Strongest versus weakest available price path

enVVeno Medical is -95.9% for its five-year window; GlucoTrack is -100.0% for its five-year window.

Open enVVeno Medical in Companies Radar Open GlucoTrack in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.00B for Co-Diagnostics to $0.00B for Lyra Therapeutics. Entity and filing-period labels remain visible on the company cards.

Open Co-Diagnostics in Companies Radar Open Lyra Therapeutics in Companies Radar

Anomalies

Lyra Therapeutics has the widest attention-readiness rank gap

It ranks #3 by measured news attention (12.5%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Lyra Therapeutics in Companies Radar

GlucoTrack shows a price-operating divergence to inspect

Its displayed filing-revenue change is +378.3% while its available monthly-close return is -100.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open GlucoTrack in Companies Radar

Explanations

Attention measures coverage volume, not quality

Co-Diagnostics's 39.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Co-Diagnostics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Co-Diagnostics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 48/100 score.

Open Co-Diagnostics in Companies Radar

Stress-test the largest divergence before forming a view

Compare GlucoTrack's profile with enVVeno Medical's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open GlucoTrack in Companies Radar Open enVVeno Medical in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.